PD14-07 TRENDS IN MEDICARE PART D SPENDING ON MIRABEGRON AND IMPLICATIONS OF THE INFLATION

Abstract

You have accessJournal of UrologyCME1 Apr 2023PD14-07 TRENDS IN MEDICARE PART D SPENDING ON MIRABEGRON AND IMPLICATIONS OF THE INFLATION REDUCTION ACT OF 2022 Brittany Berk, Elodi Dielubanza, and Thomas Hwang Brittany BerkBrittany Berk More articles by this author , Elodi DielubanzaElodi Dielubanza More articles by this author , and Thomas HwangThomas Hwang More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003261.07AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Mirabegron, a beta-3 adrenergic agonist indicated for the treatment of overactive bladder, is one of the costliest drugs for Medicare. In 2022, the US Congress enacted the Inflation Reduction Act, which for the first time allows Medicare to negotiate the price of certain costly drugs for Part D beneficiaries. This study analyzed trends in Part D spending on mirabegron and assessed the potential impact of the Inflation Reduction Act. METHODS: We obtained wholesale acquisition costs for mirabegron from Truven Health Micromedex as of October 2022; total Medicare Part D and per-beneficiary spending and utilization for 2016-2020 from Medicare’s 2020 Drug Spending database; estimated total rebates from SSR Health; and inflation data from Bureau of Labor Statistics. We calculated the nominal and inflation-adjusted change in prices for mirabegron since its launch in 2012, as well as the change in total Medicare Part D expenditures on the drug from 2016-2020. Finally, we compared estimated rebates in 2020 with minimum statutory discounts for negotiation-selected products under the Inflation Reduction Act. RESULTS: In 2020, Medicare Part D spending on mirabegron was $1.7 billion, ranking it among the top 10 likely negotiation-eligible drugs for Medicare under the Inflation Reduction Act in 2026. Part D spending on mirabegron increased by 3.37-times from 2016 ($518.6 million) to 2020. After accounting for estimated rebates, Part D net spending on mirabegron increased by an estimated 123.5% from 2016-2020. Since market launch in 2012, the wholesale acquisition cost for mirabegron has increased by 106.1% unadjusted and 68.9% on inflation-adjusted basis. Under the Inflation Reduction Act, the minimum statutory discount for mirabegron would be 25% if selected for negotiation in 2026, compared to an estimated total rebate level in 2020 of 65%. CONCLUSIONS: Medicare gross and net spending on mirabegron has grown significantly over the past decade, partly due to rapid price increases. Mirabegron may be one of the first medications (overall and for urology) selected for pricing negotiations under the Inflation Reduction Act. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e415 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Brittany Berk More articles by this author Elodi Dielubanza More articles by this author Thomas Hwang More articles by this author Expand All Advertisement PDF downloadLoading ...